Status:
COMPLETED
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
Lead Sponsor:
Johnson & Johnson Private Limited
Conditions:
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the effectiveness (overall response rate \[ORR\] and time to progression \[TPP\]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) ...
Eligibility Criteria
Inclusion
- Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
- CLL or MCL participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 mg) based on independent clinical judgment of treating physicians
Exclusion
- \- Any contraindications to ibrutinib use according to the current version of the Prescribing information in India
Key Trial Info
Start Date :
April 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03476655
Start Date
April 28 2018
End Date
May 31 2019
Last Update
February 3 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Apollo Hospitals International Limited
Ahmedabad, India, 382428
2
Healthcare Global (HCG) Hospital
Bangalore, India, 560013
3
Fortis Memorial Research Institute
Gurgaon, India, 122002
4
Basavatarakam Indo-American Hospital
Hyderabad, India, 500034